PHAXIAM Therapeutics S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHXM.PA research report →
About the company
PHAXIAM Therapeutics S. A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.
- CEO
- Thibaut du Fayet
- IPO
- 2013
- Employees
- 68
- HQ
- Lyon, FR
Price Chart
- Market Cap
- $1.01M
- P/E
- -0.02
- P/S
- 0.76
- P/B
- 0.02
- EV/EBITDA
- -0.17
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1784.31%
- Net Margin
- -1771.34%
- ROE
- -95.68%
- ROIC
- -56.27%
- Revenue
- $1.33M · -80.05%
- Net Income
- $-23,488,000 · -10201.75%
- EPS
- $-5.00 · -7263.77%
- Op Income
- $-23,660,000
- FCF YoY
- 23.16%
- 52W High
- $2.15
- 52W Low
- $0.03
- 50D MA
- $0.19
- 200D MA
- $1.19
- Beta
- 1.74
- Avg Volume
- 100.62K
Get TickerSpark's AI analysis on PHXM.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our PHXM.PA coverage
Recent articles, reports, and earnings notes.
No research on PHXM.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PHXM.PA report →Similar companies
Peers in the same neighborhood.